In Vivo Efficacy of Novel Monobactam LYS228 in Murine Models of Carbapenemase-Producing Klebsiella pneumoniae Infection

W. J. Weiss; M. E. Pulse; P. Nguyen; E. J. Growcott

doi:10.1128/AAC.02214-18

In Vivo Efficacy of Novel Monobactam LYS228 in Murine Models of Carbapenemase-Producing Klebsiella pneumoniae Infection

W. J. Weiss, M. E. Pulse, P. Nguyen, E. J. Growcott

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

LYS228 has potent antibacterial activity against carbapenem-resistant strains of Enterobacteriaceae. LYS228 was efficacious in neutropenic thigh models established with Klebsiella pneumoniae producing KPC-2 or NDM-1; pretreatment with uranyl nitrate considerably shifted calculated static doses of LYS228. In murine ascending pyelonephritis, LYS228 reduced bacterial burden in kidney, urine, and bladder. The successful treatment of murine infection models established with carbapenem-resistant K. pneumoniae further supports the clinical development of LYS228.

Original language	English
Article number	e02214-18
Journal	Antimicrobial agents and chemotherapy
Volume	63
Issue number	4
DOIs	https://doi.org/10.1128/AAC.02214-18
State	Published - Apr 2019

Keywords

LYS228
Neutropenic thigh model
Pyelonephritis

Access to Document

10.1128/AAC.02214-18

Cite this

@article{71d7b30918064cb9a00a54bce7220dde,

title = "In Vivo Efficacy of Novel Monobactam LYS228 in Murine Models of Carbapenemase-Producing Klebsiella pneumoniae Infection",

abstract = "LYS228 has potent antibacterial activity against carbapenem-resistant strains of Enterobacteriaceae. LYS228 was efficacious in neutropenic thigh models established with Klebsiella pneumoniae producing KPC-2 or NDM-1; pretreatment with uranyl nitrate considerably shifted calculated static doses of LYS228. In murine ascending pyelonephritis, LYS228 reduced bacterial burden in kidney, urine, and bladder. The successful treatment of murine infection models established with carbapenem-resistant K. pneumoniae further supports the clinical development of LYS228.",

keywords = "LYS228, Neutropenic thigh model, Pyelonephritis",

author = "Weiss, {W. J.} and Pulse, {M. E.} and P. Nguyen and Growcott, {E. J.}",

note = "Funding Information: This work was funded by Novartis as part of a drug discovery project. E.J.G. holds stock in Novartis. Publisher Copyright: Copyright {\textcopyright} 2019 American Society for Microbiology. All Rights Reserved.",

year = "2019",

month = apr,

doi = "10.1128/AAC.02214-18",

language = "English",

volume = "63",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "4",

}

TY - JOUR

T1 - In Vivo Efficacy of Novel Monobactam LYS228 in Murine Models of Carbapenemase-Producing Klebsiella pneumoniae Infection

AU - Weiss, W. J.

AU - Pulse, M. E.

AU - Nguyen, P.

AU - Growcott, E. J.

N1 - Funding Information: This work was funded by Novartis as part of a drug discovery project. E.J.G. holds stock in Novartis. Publisher Copyright: Copyright © 2019 American Society for Microbiology. All Rights Reserved.

PY - 2019/4

Y1 - 2019/4

N2 - LYS228 has potent antibacterial activity against carbapenem-resistant strains of Enterobacteriaceae. LYS228 was efficacious in neutropenic thigh models established with Klebsiella pneumoniae producing KPC-2 or NDM-1; pretreatment with uranyl nitrate considerably shifted calculated static doses of LYS228. In murine ascending pyelonephritis, LYS228 reduced bacterial burden in kidney, urine, and bladder. The successful treatment of murine infection models established with carbapenem-resistant K. pneumoniae further supports the clinical development of LYS228.

AB - LYS228 has potent antibacterial activity against carbapenem-resistant strains of Enterobacteriaceae. LYS228 was efficacious in neutropenic thigh models established with Klebsiella pneumoniae producing KPC-2 or NDM-1; pretreatment with uranyl nitrate considerably shifted calculated static doses of LYS228. In murine ascending pyelonephritis, LYS228 reduced bacterial burden in kidney, urine, and bladder. The successful treatment of murine infection models established with carbapenem-resistant K. pneumoniae further supports the clinical development of LYS228.

KW - LYS228

KW - Neutropenic thigh model

KW - Pyelonephritis

UR - http://www.scopus.com/inward/record.url?scp=85063669442&partnerID=8YFLogxK

U2 - 10.1128/AAC.02214-18

DO - 10.1128/AAC.02214-18

M3 - Article

C2 - 30642927

AN - SCOPUS:85063669442

SN - 0066-4804

VL - 63

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 4

M1 - e02214-18

ER -

In Vivo Efficacy of Novel Monobactam LYS228 in Murine Models of Carbapenemase-Producing Klebsiella pneumoniae Infection

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this